How preconceived ideas of sample size nearly soured a great project

Pharma Specific Conjoint offered an ideal solution for our client.  However, the significantly smaller sample size, compared to that of discrete-choice conjoint, lead to the project being met with reservations. A solution was needed to demonstrate the accuracy of our methodology.


Back to Case Studies

The asset in dermatology looked promising

Our client’s dermatology asset was in late phase trials and initial data read-outs looked promising. Internal expectations were high, although there was still uncertainty around the asset’s profile.

Inpharmation’s experience in dermatology, along with our Pharma-Specific Conjoint™ platform, offered the ideal solution to inform the asset’s market-share potential.

However, a new project lead had reservations

After the project had been commissioned, a new project lead joined the client’s team. The lead had experience with discrete-choice conjoint and was skeptical of our approach because of the significantly smaller sample size.

This was understandable because the lead had only used discrete-choice conjoint in the past, and, with discrete-choice conjoint, much larger sample sizes are needed. There is lots of research supporting this:

  • “Only when the random sample size is 500 or greater do the estimates start to cluster around the true parameters.”
    Behavioral Research Group

It was too late to change course as the project had already been commissioned and internal deadlines had to be met. It would have been too time consuming to change approach.

A solution was needed to prove the accuracy of Pharma-Specific Conjoint… 

Download the full Case Study by filling in the form:

By clicking on the “Submit Request” button you are providing consent for us to store your data and contact you. You may withdraw your consent at any time by instructing us at .

View our Privacy Policy for more information.

Please note that Inpharmation literature and case study materials constitute Inpharmation intellectual property and are intended for the pharmaceutical industry. Inpharmation is under no obligation to distribute these materials to non-pharmaceutical industry employees or competitors.

Scroll Top